#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow

Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla

#Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip

#EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY

Comparison of disease activity and PROs in AxSpA vs. AxPsA ⭐️AxSpA ⬆️ uveitis and IBD ⭐️AxPsA ⬆️enthesitis and dactylitis ⭐️AxSpA pts ⬆️pain, spinal pain PROs ⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb

Secukinumab effective in AS patients, irrespective of gender AQUILA 52 week study ⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women ⭐️women had overall higher disease burden in global functioning and depressive mood POS0899 #EULAR2021 @RheumNow

C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA ⭐️82% ⬇️ in uveitis flare event ⭐️reduction in axSpA disease activity ⭐️no new safety signals POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY

Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx

In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki

• https://ard.bmj.com/content/80/Suppl_1/27.1.full

Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD

• https://ard.bmj.com/content/80/Suppl_1/27.2

Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z

• https://ard.bmj.com/content/80/Suppl_1/26.1

Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smaller deltas between ASAS40 results in PBO vs nr-axSpA compared to axSpA vs PBO in MEASURE 2, PREVENT, COAST-V, COAST-X, RAPID, C-axSpAnd. Dr. Deodhar #EULAR2021 @RheumNow https://t.co/V8zlZdGltQ

Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar discusses differences in tx withdrawal/dose reduction(PBO) shown in RE-EMBARK, ABILITY-3, C-OPTIMISE. #EULAR2021 @RheumNow https://t.co/wVYsPYFLAi

Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 ⁦@RheumNow⁩ https://t.co/OdlQvGyNfY